Haematologica (Dec 2023)

Granulocyte transfusions in severe aplastic anemia

  • Roma V. Rajput,
  • Vaani Shah,
  • Ruba N. Shalhoub,
  • Kamille West-Mitchell,
  • Nu Ri Cha,
  • Cathy Conry-Cantilena,
  • Susan F. Leitman,
  • David J. Young,
  • Brian Wells,
  • Georg Aue,
  • Cynthia E. Dunbar,
  • Bhavisha A. Patel,
  • Richard W. Childs,
  • Neal S. Young,
  • Colin O. Wu,
  • Emma M. Groarke,
  • Shelley S. Kalsi

DOI
https://doi.org/10.3324/haematol.2023.283826
Journal volume & issue
Vol. 109, no. 6

Abstract

Read online

Patients with severe aplastic anemia (SAA) are at high risk of morbidity and mortality due to severe infections. We aimed to characterize the role of granulocyte transfusions (GT) in SAA. Primary outcomes were survival after the first GT, including overall survival (OS) at last follow up, survival to discharge, and receipt of a hematopoietic stem cell transplant (HSCT) Secondary outcomes included evaluation of clinical response at 7 and 30 days after initiation of GT, using a clinical scoring system incorporating microbiological and radiographic response. Twenty-eight SAA patients underwent 30 GT courses with a per-dose median of 1.28x109 granulocytes/kilogram (range, 0.45-4.52x109). OS from initial GT to median last follow up (551 days) was 50%, with 39% (11/28) alive at last follow up. Sixty-four percent (18/28) of all patients survived to hospital discharge. Patients with a complete or partial response, or stable infection, at 30 days had significantly better OS compared to non-responders (P=0.0004). Eighty-six percent (18/21) of patients awaiting HSCT during GT underwent a transplant and 62% (13/21) survived to post-HSCT discharge. Sex, type of infection, and percentage of days with absolute neutrophil count >0.2x109/L during the course of GT were not predictive of survival (P=0.52, P=0.7 and P=0.28, respectively). Nine of 28 (32%) patients developed new or increased human leukocyte antigen alloimmunization during their GT course. GT in SAA may have an impact on survival in those patients with improvement or stabilization of their underlying infection. Alloimmunization can occur and OS in this population remains poor, but GT may be a useful tool to bridge patients to curative treatment with HSCT.